PCM
ABUS icon

Prelude Capital Management’s Arbutus Biopharma ABUS Stock Holding History

Prelude Capital Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$114K Hold
25,318
– – 0.01% 1030
2025
Q4 		$122K Hold
25,318
– – 0.01% 1154
2025
Q3 		$115K Hold
25,318
– – 0.01% 1036
2025
Q2 		$78.2K Buy
+25,318
New +$84.1K 0.01% 935
2023
Q3 		– Sell
-18,790
Closed -$43.2K – 1110
2023
Q2 		$43.2K Sell
18,790
-12,409
-40% -$32.3K ﹤0.01% 982
2023
Q1 		$94.5K Sell
31,199
-8,950
-22% -$25.2K 0.01% 957
2022
Q4 		$93.5K Sell
40,149
-13,728
-25% -$32.8K ﹤0.01% 1081
2022
Q3 		$103K Sell
53,877
-14,688
-21% -$34.6K ﹤0.01% 1165
2022
Q2 		$186K Buy
68,565
+9,065
+15% +$23.2K 0.01% 1306
2022
Q1 		$177K Buy
59,500
+15,200
+34% +$46.5K 0.01% 1302
2021
Q4 		$172K Buy
44,300
+5,300
+14% +$20.6K ﹤0.01% 1604
2021
Q3 		$167K Buy
+39,000
New +$130K ﹤0.01% 1404
2021
Q1 		– Sell
-45,100
Closed -$160K – 1504
2020
Q4 		$160K Buy
45,100
+100
+0.2% +$350 ﹤0.01% 1146
2020
Q3 		$141K Buy
+45,000
New +$137K 0.01% 791
2017
Q4 		– Sell
-3,400
Closed -$21K – 1316
2017
Q3 		$21K Buy
+3,400
New +$14.5K ﹤0.01% 1308
2016
Q3 		– Sell
-100
Closed – – 1560
2016
Q2 		$0 Buy
+100
New +$423 ﹤0.01% 1548
2015
Q1 		– Sell
-3,000
Closed -$46K – 1904
2014
Q4 		$46K Buy
+3,000
New +$51.8K 0.01% 1268

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Prelude Capital Management's ABUS Position: Q1 2026 in Review

Prelude Capital Management held its Arbutus Biopharma (ABUS) position steady in Q1 2026 at 25,318 shares worth $114K. The position accounts for 0.01% of the portfolio, ranked #1030.

Prelude Capital Management first reported a position in ABUS in Q4 2014 and has held it in 17 quarters since. The position peaked at $186K in Q2 2022. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Prelude Capital Management held 25,318 shares of Arbutus Biopharma worth $114K as of Q1 2026.
  • Prelude Capital Management left its Arbutus Biopharma share count unchanged in Q1 2026.
  • Arbutus Biopharma made up 0.01% of Prelude Capital Management's portfolio in Q1 2026, its #1030 holding.
  • Prelude Capital Management first reported a position in Arbutus Biopharma in Q4 2014 and has held it in 17 quarters since.
  • Prelude Capital Management's Arbutus Biopharma position peaked at $186K in Q2 2022.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.